{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:13:56Z","timestamp":1794960836903,"version":"4.9.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","award":["1-16-PMF-001"],"award-info":[{"award-number":["1-16-PMF-001"]}],"id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["17PRE33410983"],"award-info":[{"award-number":["17PRE33410983"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA014520"],"award-info":[{"award-number":["P30CA014520"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002373"],"award-info":[{"award-number":["UL1TR002373"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008028","name":"UW | School of Medicine and Public Health, University of Wisconsin-Madison","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG056771, R01AG062328"],"award-info":[{"award-number":["R01AG056771, R01AG062328"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Aeonian Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Rapamycin, an inhibitor of mechanistic Target Of Rapamycin Complex 1 (mTORC1), extends lifespan and shows strong potential for the treatment of age-related diseases. However, rapamycin exerts metabolic and immunological side effects mediated by off-target inhibition of a second mTOR-containing complex, mTOR complex 2. Here, we report the identification of DL001, a FKBP12-dependent rapamycin analog 40x more selective for mTORC1 than rapamycin. DL001 inhibits mTORC1 in cell culture lines and in vivo in C57BL\/6J mice, in which DL001 inhibits mTORC1 signaling without impairing glucose homeostasis and with substantially reduced or no side effects on lipid metabolism and the immune system. In cells, DL001 efficiently represses elevated mTORC1 activity and restores normal gene expression to cells lacking a functional tuberous sclerosis complex. Our results demonstrate that highly selective pharmacological inhibition of mTORC1 can be achieved in vivo, and that selective inhibition of mTORC1 significantly reduces the side effects associated with conventional rapalogs.<\/jats:p>","DOI":"10.1038\/s41467-019-11174-0","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T10:03:00Z","timestamp":1563530580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":178,"title":["A novel rapamycin analog is highly selective for mTORC1 in vivo"],"prefix":"10.1038","volume":"10","author":[{"given":"Katherine H.","family":"Schreiber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian I.","family":"Arriola Apelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline A.","family":"Brinkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Velarde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faizan A.","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6033-9415","authenticated-orcid":false,"given":"Chen-Yu","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma L.","family":"Baar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn A.","family":"Carbajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn S.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9384-5501","authenticated-orcid":false,"given":"Regina","family":"Brunauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shany E.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stelios T.","family":"Tzannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian K.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0079-4467","authenticated-orcid":false,"given":"Dudley W.","family":"Lamming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,19]]},"reference":[{"key":"11174_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cmet.2009.11.010","volume":"11","author":"I Bjedov","year":"2010","unstructured":"Bjedov, I. et al. Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. Cell Metab. 11, 35\u201346 (2010).","journal-title":"Cell Metab."},{"key":"11174_CR2","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nature08221","volume":"460","author":"DE Harrison","year":"2009","unstructured":"Harrison, D. E. et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460, 392\u2013395 (2009).","journal-title":"Nature"},{"key":"11174_CR3","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.cmet.2012.04.007","volume":"15","author":"S Robida-Stubbs","year":"2012","unstructured":"Robida-Stubbs, S. et al. TOR signaling and rapamycin influence longevity by regulating SKN-1\/Nrf and DAF-16\/FoxO. Cell Metab. 15, 713\u2013724 (2012).","journal-title":"Cell Metab."},{"key":"11174_CR4","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1101\/gad.1381406","volume":"20","author":"RW Powers 3rd","year":"2006","unstructured":"Powers, R. W. 3rd, Kaeberlein, M., Caldwell, S. D., Kennedy, B. K. & Fields, S. Extension of chronological life span in yeast by decreased TOR pathway signaling. Genes Dev. 20, 174\u2013184 (2006).","journal-title":"Genes Dev."},{"key":"11174_CR5","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1474-9726.2011.00791.x","volume":"11","author":"S Majumder","year":"2012","unstructured":"Majumder, S. et al. Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1beta and enhancing NMDA signaling. Aging Cell 11, 326\u2013335 (2012).","journal-title":"Aging Cell"},{"key":"11174_CR6","doi-asserted-by":"publisher","first-page":"e9979","DOI":"10.1371\/journal.pone.0009979","volume":"5","author":"P Spilman","year":"2010","unstructured":"Spilman, P. et al. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS ONE 5, e9979 (2010).","journal-title":"PLoS ONE"},{"key":"11174_CR7","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/acel.12203","volume":"13","author":"DF Dai","year":"2014","unstructured":"Dai, D. F. et al. Altered proteome turnover and remodeling by short-term caloric restriction or rapamycin rejuvenate the aging heart. Aging Cell 13, 529\u2013539 (2014).","journal-title":"Aging Cell"},{"key":"11174_CR8","doi-asserted-by":"publisher","first-page":"e62459","DOI":"10.1371\/journal.pone.0062459","volume":"8","author":"S Ozcelik","year":"2013","unstructured":"Ozcelik, S. et al. Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice. PLoS ONE 8, e62459 (2013).","journal-title":"PLoS ONE"},{"key":"11174_CR9","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/j.1474-9726.2012.00832.x","volume":"11","author":"JE Wilkinson","year":"2012","unstructured":"Wilkinson, J. E. et al. Rapamycin slows aging in mice. Aging Cell 11, 675\u2013682 (2012).","journal-title":"Aging Cell"},{"key":"11174_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11357-017-9972-z","volume":"39","author":"SR Urfer","year":"2017","unstructured":"Urfer, S. R. et al. A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs. Geroscience 39, 117\u2013127 (2017).","journal-title":"Geroscience"},{"key":"11174_CR11","doi-asserted-by":"publisher","first-page":"268ra179","DOI":"10.1126\/scitranslmed.3009892","volume":"6","author":"JB Mannick","year":"2014","unstructured":"Mannick, J. B. et al. mTOR inhibition improves immune function in the elderly. Sci. Transl. Med 6, 268ra179 (2014).","journal-title":"Sci. Transl. Med"},{"key":"11174_CR12","doi-asserted-by":"publisher","first-page":"31793","DOI":"10.3402\/pba.v6.31793","volume":"6","author":"M Lelegren","year":"2016","unstructured":"Lelegren, M., Liu, Y., Ross, C., Tardif, S. & Salmon, A. B. Pharmaceutical inhibition of mTOR in the common marmoset: effect of rapamycin on regulators of proteostasis in a non-human primate. Pathobiol. Aging Age Relat. Dis. 6, 31793 (2016).","journal-title":"Pathobiol. Aging Age Relat. Dis."},{"key":"11174_CR13","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/CAD.0000000000000207","volume":"26","author":"J Trelinska","year":"2015","unstructured":"Trelinska, J. et al. Complications of mammalian target of rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening. Anti-cancer drugs 26, 437\u2013442 (2015).","journal-title":"Anti-cancer drugs"},{"key":"11174_CR14","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1172\/JCI64099","volume":"123","author":"DW Lamming","year":"2013","unstructured":"Lamming, D. W., Ye, L., Sabatini, D. M. & Baur, J. A. Rapalogs and mTOR inhibitors as anti-aging therapeutics. J. Clin. Invest 123, 980\u2013989 (2013).","journal-title":"J. Clin. Invest"},{"key":"11174_CR15","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.cmet.2016.05.009","volume":"23","author":"BK Kennedy","year":"2016","unstructured":"Kennedy, B. K. & Lamming, D. W. The Mechanistic Target of Rapamycin: The Grand ConducTOR of Metabolism and Aging. Cell Metab. 23, 990\u20131003 (2016).","journal-title":"Cell Metab."},{"key":"11174_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.diabres.2015.09.014","volume":"110","author":"B Verges","year":"2015","unstructured":"Verges, B. & Cariou, B. mTOR inhibitors and diabetes. Diabetes Res Clin. Pr. 110, 101\u2013108 (2015).","journal-title":"Diabetes Res Clin. Pr."},{"key":"11174_CR17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.trre.2014.03.002","volume":"28","author":"B Kaplan","year":"2014","unstructured":"Kaplan, B., Qazi, Y. & Wellen, J. R. Strategies for the management of adverse events associated with mTOR inhibitors. Transplant. Rev. 28, 126\u2013133 (2014).","journal-title":"Transplant. Rev."},{"key":"11174_CR18","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1470-2045(15)00051-0","volume":"16","author":"SA Hurvitz","year":"2015","unstructured":"Hurvitz, S. A. et al. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol. 16, 816\u2013829 (2015).","journal-title":"Lancet Oncol."},{"key":"11174_CR19","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao, J. C. et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387, 968\u2013977 (2016).","journal-title":"Lancet"},{"key":"11174_CR20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/acel.12405","volume":"15","author":"SI Arriola Apelo","year":"2016","unstructured":"Arriola Apelo, S. I. et al. Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system. Aging Cell 15, 28\u201338 (2016).","journal-title":"Aging Cell"},{"key":"11174_CR21","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1093\/gerona\/glw064","volume":"71","author":"SI Arriola Apelo","year":"2016","unstructured":"Arriola Apelo, S. I., Pumper, C. P., Baar, E. L., Cummings, N. E. & Lamming, D. W. Intermittent Administration of Rapamycin Extends the Life Span of Female C57BL\/6J Mice. J. Gerontol. A Biol. Sci. Med Sci. 71, 876\u2013881 (2016).","journal-title":"J. Gerontol. A Biol. Sci. Med Sci."},{"key":"11174_CR22","doi-asserted-by":"publisher","first-page":"eaaq1564","DOI":"10.1126\/scitranslmed.aaq1564","volume":"10","author":"JB Mannick","year":"2018","unstructured":"Mannick, J. B. et al. TORC1 inhibition enhances immune function and reduces infections in the elderly. Sci. Transl. Med 10, eaaq1564 (2018).","journal-title":"Sci. Transl. Med"},{"key":"11174_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.exger.2017.12.026","volume":"105","author":"E Kraig","year":"2018","unstructured":"Kraig, E. et al. A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects. Exp. Gerontol. 105, 53\u201369 (2018).","journal-title":"Exp. Gerontol."},{"key":"11174_CR24","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/acel.12194","volume":"13","author":"RA Miller","year":"2014","unstructured":"Miller, R. A. et al. Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell 13, 468\u2013477 (2014).","journal-title":"Aging Cell"},{"key":"11174_CR25","doi-asserted-by":"publisher","first-page":"e16351","DOI":"10.7554\/eLife.16351","volume":"5","author":"A Bitto","year":"2016","unstructured":"Bitto, A. et al. Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice. eLife 5, e16351 (2016).","journal-title":"eLife"},{"key":"11174_CR26","doi-asserted-by":"publisher","unstructured":"Dumas S. N., Lamming D. W. Next generation strategies for geroprotection via mTORC1 inhibition. J. Gerontol. A Biol. Sci. Med. Sci.\u00a0glz056 https:\/\/doi.org\/10.1093\/gerona\/glz056 (2019). [Epub ahead of print]","DOI":"10.1093\/gerona\/glz056"},{"key":"11174_CR27","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","volume":"14","author":"DD Sarbassov","year":"2004","unstructured":"Sarbassov, D. D. et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14, 1296\u20131302 (2004).","journal-title":"Curr. Biol."},{"key":"11174_CR28","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1126\/science.1215135","volume":"335","author":"DW Lamming","year":"2012","unstructured":"Lamming, D. W. et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335, 1638\u20131643 (2012).","journal-title":"Science"},{"key":"11174_CR29","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1182\/blood-2006-06-030833","volume":"109","author":"Z Zeng","year":"2007","unstructured":"Zeng, Z. et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 109, 3509\u20133512 (2007).","journal-title":"Blood"},{"key":"11174_CR30","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/acel.12313","volume":"14","author":"KH Schreiber","year":"2015","unstructured":"Schreiber, K. H. et al. Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins. Aging Cell 14, 265\u2013273 (2015).","journal-title":"Aging Cell"},{"key":"11174_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","volume":"22","author":"DD Sarbassov","year":"2006","unstructured":"Sarbassov, D. D. et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB. Mol. Cell 22, 159\u2013168 (2006).","journal-title":"Mol. Cell"},{"key":"11174_CR32","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1107\/S0907444998014747","volume":"55","author":"J Liang","year":"1999","unstructured":"Liang, J., Choi, J. & Clardy, J. Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 A resolution. Acta Crystallogr D. Biol. Crystallogr 55, 736\u2013744 (1999).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"11174_CR33","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1128\/MCB.00678-12","volume":"33","author":"AM Marz","year":"2013","unstructured":"Marz, A. M., Fabian, A. K., Kozany, C., Bracher, A. & Hausch, F. Large FK506-binding proteins shape the pharmacology of rapamycin. Mol. Cell Biol. 33, 1357\u20131367 (2013).","journal-title":"Mol. Cell Biol."},{"key":"11174_CR34","doi-asserted-by":"publisher","first-page":"742","DOI":"10.18632\/aging.100688","volume":"6","author":"Y Liu","year":"2014","unstructured":"Liu, Y. et al. Rapamycin-induced metabolic defects are reversible in both lean and obese mice. Aging (Albany NY) 6, 742\u2013754 (2014).","journal-title":"Aging (Albany NY)"},{"key":"11174_CR35","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1083\/jcb.200403069","volume":"166","author":"LS Harrington","year":"2004","unstructured":"Harrington, L. S. et al. The TSC1\u20132 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166, 213\u2013223 (2004).","journal-title":"J. Cell Biol."},{"key":"11174_CR36","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1126\/science.1199498","volume":"332","author":"PP Hsu","year":"2011","unstructured":"Hsu, P. P. et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317\u20131322 (2011).","journal-title":"Science"},{"key":"11174_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11365","volume":"7","author":"Y Tang","year":"2016","unstructured":"Tang, Y. et al. Adipose tissue mTORC2 regulates ChREBP-driven de novo lipogenesis and hepatic glucose metabolism. Nat. Commun. 7, 11365 (2016).","journal-title":"Nat. Commun."},{"key":"11174_CR38","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.1113\/JP274203","volume":"595","author":"M Kleinert","year":"2017","unstructured":"Kleinert, M. et al. Mammalian target of rapamycin complex 2 regulates muscle glucose uptake during exercise in mice. J. Physiol. 595, 4845\u20134855 (2017).","journal-title":"J. Physiol."},{"key":"11174_CR39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1128\/MCB.01405-07","volume":"28","author":"A Kumar","year":"2008","unstructured":"Kumar, A. et al. Muscle-specific deletion of rictor impairs insulin-stimulated glucose transport and enhances Basal glycogen synthase activity. Mol. Cell Biol. 28, 61\u201370 (2008).","journal-title":"Mol. Cell Biol."},{"key":"11174_CR40","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.2337\/db09-1061","volume":"59","author":"A Kumar","year":"2010","unstructured":"Kumar, A. et al. Fat cell-specific ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism. Diabetes 59, 1397\u20131406 (2010).","journal-title":"Diabetes"},{"key":"11174_CR41","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/acel.12256","volume":"13","author":"DW Lamming","year":"2014","unstructured":"Lamming, D. W. et al. Depletion of Rictor, an essential protein component of mTORC2, decreases male lifespan. Aging Cell 13, 911\u2013917 (2014).","journal-title":"Aging Cell"},{"key":"11174_CR42","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00280-016-3050-6","volume":"78","author":"D de Wit","year":"2016","unstructured":"de Wit, D. et al. Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer. Cancer Chemother. Pharm. 78, 63\u201371 (2016).","journal-title":"Cancer Chemother. Pharm."},{"key":"11174_CR43","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/S1053-2498(02)01221-4","volume":"22","author":"JM Kovarik","year":"2003","unstructured":"Kovarik, J. M. et al. Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. J. Heart Lung Transpl. 22, 1117\u20131125 (2003).","journal-title":"J. Heart Lung Transpl."},{"key":"11174_CR44","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1111\/acel.12097","volume":"12","author":"DW Lamming","year":"2013","unstructured":"Lamming, D. W. et al. Young and old genetically heterogeneous HET3 mice on a rapamycin diet are glucose intolerant but insulin sensitive. Aging Cell 12, 712\u2013718 (2013).","journal-title":"Aging Cell"},{"key":"11174_CR45","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.cmet.2013.08.002","volume":"18","author":"DW Lamming","year":"2013","unstructured":"Lamming, D. W. & Sabatini, D. M. A Central role for mTOR in lipid homeostasis. Cell Metab. 18, 465\u2013469 (2013).","journal-title":"Cell Metab."},{"key":"11174_CR46","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.cell.2011.06.034","volume":"146","author":"TR Peterson","year":"2011","unstructured":"Peterson, T. R. et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 146, 408\u2013420 (2011).","journal-title":"Cell"},{"key":"11174_CR47","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s11745-010-3488-y","volume":"45","author":"GA Soliman","year":"2010","unstructured":"Soliman, G. A., Acosta-Jaquez, H. A. & Fingar, D. C. mTORC1 inhibition via rapamycin promotes triacylglycerol lipolysis and release of free fatty acids in 3T3-L1 adipocytes. Lipids 45, 1089\u20131100 (2010).","journal-title":"Lipids"},{"key":"11174_CR48","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.1128\/MCB.01584-12","volume":"33","author":"P Chakrabarti","year":"2013","unstructured":"Chakrabarti, P. et al. Insulin inhibits lipolysis in adipocytes via the evolutionarily conserved mTORC1-Egr1-ATGL-mediated pathway. Mol. Cell Biol. 33, 3659\u20133666 (2013).","journal-title":"Mol. Cell Biol."},{"key":"11174_CR49","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1146\/annurev-immunol-020711-075024","volume":"30","author":"JD Powell","year":"2012","unstructured":"Powell, J. D., Pollizzi, K. N., Heikamp, E. B. & Horton, M. R. Regulation of immune responses by mTOR. Annu. Rev. Immunol. 30, 39\u201368 (2012).","journal-title":"Annu. Rev. Immunol."},{"key":"11174_CR50","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1097\/01.TP.0000151630.25127.3A","volume":"79","author":"E Mahe","year":"2005","unstructured":"Mahe, E. et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 79, 476\u2013482 (2005).","journal-title":"Transplantation"},{"key":"11174_CR51","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/acel.12280","volume":"14","author":"EL Goldberg","year":"2015","unstructured":"Goldberg, E. L. et al. Lifespan-extending caloric restriction or mTOR inhibition impair adaptive immunity of old mice by distinct mechanisms. Aging Cell 14, 130\u2013138 (2015).","journal-title":"Aging Cell"},{"key":"11174_CR52","doi-asserted-by":"publisher","first-page":"757","DOI":"10.4049\/jimmunol.1400188","volume":"193","author":"EL Goldberg","year":"2014","unstructured":"Goldberg, E. L., Smithey, M. J., Lutes, L. K., Uhrlaub, J. L. & Nikolich-Zugich, J. Immune memory-boosting dose of rapamycin impairs macrophage vesicle acidification and curtails glycolysis in effector CD8 cells, impairing defense against acute infections. J. Immunol. 193, 757\u2013763 (2014).","journal-title":"J. Immunol."},{"key":"11174_CR53","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.4049\/jimmunol.0903805","volume":"186","author":"Y Wang","year":"2011","unstructured":"Wang, Y. et al. Regulatory T cells require mammalian target of rapamycin signaling to maintain both homeostasis and alloantigen-driven proliferation in lymphocyte-replete mice. J. Immunol. 186, 2809\u20132818 (2011).","journal-title":"J. Immunol."},{"key":"11174_CR54","doi-asserted-by":"publisher","first-page":"e92684","DOI":"10.1371\/journal.pone.0092684","volume":"9","author":"K Makki","year":"2014","unstructured":"Makki, K. et al. Beneficial metabolic effects of rapamycin are associated with enhanced regulatory cells in diet-induced obese mice. PLoS ONE 9, e92684 (2014).","journal-title":"PLoS ONE"},{"issue":"Spec No. 2","key":"11174_CR55","doi-asserted-by":"publisher","first-page":"R251","DOI":"10.1093\/hmg\/ddi260","volume":"14","author":"DJ Kwiatkowski","year":"2005","unstructured":"Kwiatkowski, D. J. & Manning, B. D. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum. Mol. Genet 14(Spec No. 2), R251\u2013R258 (2005).","journal-title":"Hum. Mol. Genet"},{"key":"11174_CR56","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/onc.2014.17","volume":"34","author":"J Yang","year":"2015","unstructured":"Yang, J. et al. Renal tumours in a Tsc2(\u2009+\u2009\/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin. Oncogene 34, 922\u2013931 (2015).","journal-title":"Oncogene"},{"key":"11174_CR57","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1212\/WNL.0b013e3182815428","volume":"80","author":"DA Krueger","year":"2013","unstructured":"Krueger, D. A. et al. Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. Neurology 80, 574\u2013580 (2013).","journal-title":"Neurology"},{"key":"11174_CR58","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1038\/ejhg.2015.47","volume":"23","author":"DJ Kwiatkowski","year":"2015","unstructured":"Kwiatkowski, D. J. et al. Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2. Eur. J. Hum. Genet. : EJHG 23, 1665\u20131672 (2015).","journal-title":"Eur. J. Hum. Genet. : EJHG"},{"key":"11174_CR59","doi-asserted-by":"publisher","first-page":"e0180939","DOI":"10.1371\/journal.pone.0180939","volume":"12","author":"JJ Bissler","year":"2017","unstructured":"Bissler, J. J. et al. Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study. PLoS One 12, e0180939 (2017).","journal-title":"PLoS One"},{"key":"11174_CR60","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1212\/WNL.0000000000003400","volume":"87","author":"DA Krueger","year":"2016","unstructured":"Krueger, D. A. et al. Long-term treatment of epilepsy with everolimus in tuberous sclerosis. Neurology 87, 2408\u20132415 (2016).","journal-title":"Neurology"},{"key":"11174_CR61","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.molcel.2010.06.022","volume":"39","author":"K Duvel","year":"2010","unstructured":"Duvel, K. et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 39, 171\u2013183 (2010).","journal-title":"Mol. Cell"},{"key":"11174_CR62","doi-asserted-by":"publisher","first-page":"8023","DOI":"10.1074\/jbc.M900301200","volume":"284","author":"CC Thoreen","year":"2009","unstructured":"Thoreen, C. C. et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284, 8023\u20138032 (2009).","journal-title":"J. Biol. Chem."},{"key":"11174_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/srep42655","volume":"7","author":"K Li","year":"2017","unstructured":"Li, K. et al. Rheb1 deletion in myeloid cells aggravates OVA-induced allergic inflammation in mice. Sci. Rep. 7, 42655 (2017).","journal-title":"Sci. Rep."},{"key":"11174_CR64","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.3390\/ijms15011499","volume":"15","author":"W Yang","year":"2014","unstructured":"Yang, W. et al. Genetic deletion of Rheb1 in the brain reduces food intake and causes hypoglycemia with altered peripheral metabolism. Int J. Mol. Sci. 15, 1499\u20131510 (2014).","journal-title":"Int J. Mol. Sci."},{"key":"11174_CR65","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s11357-017-9997-3","volume":"39","author":"Q Tian","year":"2017","unstructured":"Tian, Q. et al. RHEB1 insufficiency in aged male mice is associated with stress-induced seizures. Geroscience 39, 557\u2013570 (2017).","journal-title":"Geroscience"},{"key":"11174_CR66","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cellsig.2013.11.009","volume":"26","author":"JW Frey","year":"2014","unstructured":"Frey, J. W., Jacobs, B. L., Goodman, C. A. & Hornberger, T. A. A role for Raptor phosphorylation in the mechanical activation of mTOR signaling. Cell Signal 26, 313\u2013322 (2014).","journal-title":"Cell Signal"},{"key":"11174_CR67","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/9780470994030.ch18","volume":"288","author":"PB Crino","year":"2007","unstructured":"Crino, P. B. Focal brain malformations: a spectrum of disorders along the mTOR cascade. Novartis Found. Symp. 288, 260\u2013272 (2007). discussion 272\u2013281.","journal-title":"Novartis Found. Symp."},{"key":"11174_CR68","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3389\/fgene.2012.00177","volume":"3","author":"L Ye","year":"2012","unstructured":"Ye, L., Varamini, B., Lamming, D. W., Sabatini, D. M. & Baur, J. A. Rapamycin has a biphasic effect on insulin sensitivity in C2C12 myotubes due to sequential disruption of mTORC1 and mTORC2. Front Genet 3, 177 (2012).","journal-title":"Front Genet"},{"key":"11174_CR69","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1113\/JP275075","volume":"596","author":"NE Cummings","year":"2018","unstructured":"Cummings, N. E. et al. Restoration of metabolic health by decreased consumption of branched-chain amino acids. J. Physiol. 596, 623\u2013645 (2018).","journal-title":"J. Physiol."},{"key":"11174_CR70","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43, e47 (2015).","journal-title":"Nucleic Acids Res"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11174-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11174-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11174-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T11:36:41Z","timestamp":1695037001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11174-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,19]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["11174"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-11174-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,19]]},"assertion":[{"value":"25 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.C.V. contributed to this manuscript while an employee of Aeonian Pharmaceuticals. S.T.Z. is the President and CEO of Aeonian Pharmaceuticals. B.K.K. is the Board Chair of Mount Tam Pharmaceuticals, which seeks to develop novel therapeutics to treat autoimmune diseases by modifying the mTOR pathway. D.W.L. has received funding from, and is a scientific advisory board member of, Aeonian Pharmaceuticals, which seeks to develop novel, selective mTOR inhibitors for the treatment of various diseases.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3194"}}